Theragen

Theragen is a private, commercial-stage medical device company that has brought the ActaStim® system to market, representing the first significant advance in spinal fusion bone growth stimulator technology in nearly two decades. Its FDA-approved device utilizes capacitive coupling electrical stimulation to promote bone healing, is designed for continuous wearability, and provides patient compliance data. The company is positioned in the large and growing spinal fusion market, targeting improved patient outcomes and reduced revision surgery rates through its clinically supported technology.

Capacitive Coupling (CC) electrical stimulation for bone growth. A wearable device that delivers a specific low-level electrical signal to upregulate bone cell proliferation and promote spinal fusion.

Theragen competes in the bone growth stimulation market, which includes other FDA-approved devices using Pulsed Electromagnetic Fields (PEMF) and Direct Current (DC) stimulation from companies like Orthofix, Bioventus, and Zimmer Biomet. ActaStim® differentiates itself with its capacitive coupling technology, claimed continuous wearability, and patient data insights, positioning itself as a modern alternative in a field with legacy devices.